Machicado Jorge D, Yadav Dhiraj
Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, 200 Lothrop Street, M-2, C-Wing, Pittsburgh, PA, 15213, USA.
Dig Dis Sci. 2017 Jul;62(7):1683-1691. doi: 10.1007/s10620-017-4510-5. Epub 2017 Mar 9.
Emerging data in the past few years suggest that acute, recurrent acute (RAP), and chronic pancreatitis (CP) represent a disease continuum. This review discusses the similarities and differences in the epidemiology of RAP and CP. RAP is a high-risk group, comprised of individuals at varying risk of progression. The premise is that RAP is an intermediary stage in the pathogenesis of CP, and a subset of RAP patients during their natural course transition to CP. Although many clinical factors have been identified, accurately predicting the probability of disease course in individual patients remains difficult. Future studies should focus on providing more precise estimates of the risk of disease transition in a cohort of patients, quantification of clinical events during the natural course of disease, and discovery of biomarkers of the different stages of the disease continuum. Availability of clinically relevant endpoints and linked biomarkers will allow more accurate prediction of the natural course of disease over intermediate- or long-term-based characteristics of an individual patient. These endpoints will also provide objective measures for use in clinical trials of interventions that aim to alter the natural course of disease.
过去几年出现的数据表明,急性胰腺炎、复发性急性胰腺炎(RAP)和慢性胰腺炎(CP)代表了一种疾病连续体。本综述讨论了RAP和CP在流行病学方面的异同。RAP是一个高危群体,由处于不同进展风险的个体组成。前提是RAP是CP发病机制中的一个中间阶段,并且一部分RAP患者在其自然病程中会转变为CP。尽管已经确定了许多临床因素,但准确预测个体患者疾病进程的可能性仍然困难。未来的研究应侧重于更精确地估计一组患者疾病转变的风险,量化疾病自然病程中的临床事件,以及发现疾病连续体不同阶段的生物标志物。临床相关终点和相关生物标志物的可用性将允许根据个体患者的中期或长期特征更准确地预测疾病的自然病程。这些终点还将为旨在改变疾病自然病程的干预措施的临床试验提供客观指标。